programmed cell death protein 1 | Клиническая онкология


Log in Registration Search for: Home Online Publication Current Issue Issue Archive Authors About Information About the Journal Focus and Scope Indexing For Authors Submission Guidelines and Requirements Peer Review Article Processing Charges Copyright and Licensing Policies Editorial Policy Plagiarism Policy Archiving Policy Policy on the Use of Artificial Intelligence (AI) and AI-Supported Technologies Open Access Procedure for the Retraction of Published Articles Ethical Issues Publication Ethics Procedure for Handling Complaints Regarding Ethical Breaches Privacy Statement International Standards and Principles of Operation
Organization of anticancer fight Tumors of the chest cavity Tumors of abdominal organs Tumors of skin, soft tissues, bones Breast tumor Oncogynecology Tumors of the head and neck Oncurology Oncohematology Radiation diagnostics, radiation therapy Experimental studies Number Т. 16, №3 (63) Magazine online All news	Keyword : programmed cell death protein 1 Pembrolizumab vs Placebo as Adjuvant Therapy for High-Risk Stage II Melanoma: Long-Term Follow-Up, Rechallenge, and Crossover in KEYNOTE-716 Т. 14, №4 (56) KEYNOTE-006 study: results of 10-year follow-up of pembrolizumab versus ipilimumab in advanced melanoma Т. 14, №4 (56)
MORION Publishing House Editorial office and publisher: 02140, Kyiv, ave. Bazhana 10A Tel.: 380 (44) 585-97-10 Specialized medical online publication for doctors, pharmacists, pharmacists, medical students and pharmaceutical universities.Disclaimer morion.ua apteka.ua pharmstandart.com.ua compendium.com.ua proximaresearch.com

Number Т. 16, №3 (63)

Magazine online

Keyword : programmed cell death protein 1